The emerging role of the intestine in metabolic diseases

Archives of Physiology and Biochemistry

Volumn 117, Issue 3, 2011, Pages 165-176

  Bradley, William D ^a   Zwingelstein, Catherine ^a   Rondinone, Cristina M ^a,b  

^a HOFFMANN LA ROCHE INC   (United States)

^b MEDIMMUNE   (United States)

Author keywords

bariatric surgery; gut hormones; incretins; microbiota; Type 2 diabetes

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; PEPTIDE YY;

ANIMAL; BARIATRIC SURGERY; CONFERENCE PAPER; GASTROINTESTINAL TRACT; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLISM; METAGENOME; MICROBIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; GASTROINTESTINAL TRACT; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFLAMMATION; INSULIN RESISTANCE; METABOLIC DISEASES; METAGENOME; OBESITY; PEPTIDE YY;

EID: 79959261020     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2011.578651     Document Type: Conference Paper

References (134)

1. Abbott CR, Small CJ, Kennedy AR, Neary NM, Sajedi A, Ghatei MA, Bloom SR. (2005). Blockade of the neuropeptide Y Y2 receptor with the specifc antagonist BIIE0246 attenuates the efect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res 1043:139-44. (Pubitemid 40603381)
2. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. (1985a). Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070-77. (Pubitemid 16231572)
3. Adrian TE, Savage AP, Sagor GR, Allen JM, Bacarese-Hamilton AJ, Tatemoto K, Polak JM, Bloom SR. (1985b). Efect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 89:494-9. (Pubitemid 15239150)
4. Ahren B. (2003). Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 3:365-72. (Pubitemid 38906794)
5. Allen JM, Fitzpatrick ML, Yeats JC, Darcy K, Adrian TE, Bloom SR. (1984). Efects of peptide YY and neuropeptide Y on gastric emptying in man. Digestion 30:255-62. (Pubitemid 15210438)
6. Ashrafan H, Athanasiou T, Li JV, Bueter M, Ahmed K, Nagpal K, Holmes E, Darzi A, Bloom SR. (2010). Diabetes resolution and hyperinsulinaemia after metabolic Roux-en-Y gastric bypass. Obes Rev 0:00-00.
7. Ashrafan H, le Roux CW. (2009). Metabolic surgery and gut hormones-a review of bariatric entero-humoral modulation. Physiol Behav 97:620-31.
8. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. (2004). Te gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 101:15718-23. (Pubitemid 39473554)
9. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. (2005). Host-bacterial mutualism in the human intestine. Science. 307:1915-20. (Pubitemid 40404694)
10. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. (2007). Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 104:979-84. (Pubitemid 46154722)
11. Bainbridge FA, Beddard AP. (1906). Secretin in relation to diabetes mellitus. Biochem J 1:429-45.
12. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. (2003). Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349:941-8. (Pubitemid 37064767)
13. Beguin P, Nagashima K, Nishimura M, Gonoi T, Seino S. (1999). PKA-mediated phosphorylation of the human K(ATP) channel:separate roles of Kir6.2 and SUR1 subunit phosphorylation. EMBO J 18:4722-32. (Pubitemid 29415526)
14. Brandt G, Park A, Wynne K, Sileno A, Jazrawi R, Woods A, Quay S, Bloom S. (2004). Nasal peptide PYY(3-36) phase 1 dose ranging and safety studies in healthy human subjects. ENDO 2004, Te 86th annual meeting of the Endocrine Society, date, New Orleans, LA. Place: Te Endocrine Society, 00-00.
15. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. (2004). Bariatric surgery: a systematic review and meta-analysis. JAMA 292:1724-37. (Pubitemid 39346675)
16. Bullock BP, Heller RS, Habener JF. (1996). Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137:2968-78. (Pubitemid 26192194)
17. Bulotta A, Hui H, Anastasi E, Bertolotto C, Boros LG, Di Mario U, Perfetti R. (2002). Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like diferentiation in response to glucagon-like peptide-1. J Mol Endocrinol 29:347-60. (Pubitemid 36024549)
18. Buteau J, Foisy S, Joly E, Prentki M. (2003). Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52:124-32. (Pubitemid 36042116)
19. Buteau J, Roduit R, Susini S, Prentki M. (1999). Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42:856-64. (Pubitemid 29325077)
20. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C et al. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:1761-72. (Pubitemid 47025442)
21. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. (2008). Changes in gut microbiota control metabolic endotoxemia-induced infammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57:1470-81.
22. Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, O'Rahilly S. (2003). Acute efects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 311:915-19. (Pubitemid 37393405)
23. Cohen RV, Schiavon CA, Pinheiro JS, Correa JL, Rubino F. (2007). Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2: a report of 2 cases. Surg Obes Relat Dis 3:195-7. (Pubitemid 46444706)
24. Creutzfeldt M. (1974). Candidate hormones of the gut. XV. Insulin-releasing factors of the gastrointestinal mucosa (Incretin). Gastroenterology 67:748-50.
25. Cummings DE, Flum DR. (2008). Gastrointestinal surgery as a treatment for diabetes. JAMA 299:341-3. (Pubitemid 351159373)
26. Cummings DE, Foster-Schubert KE, Overduin J. (2005). Ghrelin and energy balance: focus on current controversies. Curr Drug Targets 6:153-69. (Pubitemid 40394311)
27. Cummings DE, Overduin J, Foster-Schubert KE. (2004). Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 89:2608-15. (Pubitemid 38766339)
28. Cummings DE, Overduin J, Foster-Schubert KE, Carlson MJ. (2007). Role of the bypassed proximal intestine in the anti-diabetic efects of bariatric surgery. Surg Obes Relat Dis 3:109-15. (Pubitemid 46444709)
29. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ. (2002). Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346:1623-30. (Pubitemid 34755670)
30. de la Tour D, Halvorsen T, Demeterco C, Tyrberg B, Itkin-Ansari P, Loy M, Yoo SJ, Hao E, Bossie S, Levine F. (2001). Beta-cell diferentiation from a human pancreatic cell line in vitro and in vivo. Mol Endocrinol 15:476-83. (Pubitemid 32221923)
31. de Paula AL, Macedo AL, Prudente AS, Queiroz L, Schraibman V, Pinus J. (2006). Laparoscopic sleeve gastrectomy with ileal interposition ('neuroendocrine brake')\pilot study of a new operation. Surg Obes Relat Dis 2:464-7. (Pubitemid 44028838)
32. Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C. (2005). Efect of peptide YY3-36 on food intake in humans. Gastroenterology 129:1430-36. (Pubitemid 41597385)
33. Ding WG, Gromada J. (1997). Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes 46:615-21. (Pubitemid 27143377)
34. Drucker DJ. (2002). Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122:531-44. (Pubitemid 34117003)
35. Drucker DJ. (2003). Glucagon-like peptides: regulators of cell proliferation, diferentiation, and apoptosis. Mol Endocrinol 17:161-71. (Pubitemid 36183142)
36. Drucker DJ. (2006). Te biology of incretin hormones. Cell Metab 3:153-65.
37. Drucker DJ. (2007). Te role of gut hormones in glucose homeostasis. J Clin Invest 117:24-32. (Pubitemid 46048446)
38. Eckel RH, Grundy SM, Zimmet PZ. (2005). Te metabolic syndrome. Lancet 365:1415-28.
39. Egan JM, Bulotta A, Hui H, Perfetti R. (2003). GLP-1 receptor agonists are growth and diferentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev 19:115-23. (Pubitemid 36417195)
40. Ehses JA, Lee SS, Pederson RA, McIntosh CH. (2001). A new pathway for glucose-dependent insulinotropic polypeptide (GIP) receptor signaling: evidence for the involvement of phospholipase A2 in GIP-stimulated insulin secretion. J Biol Chem 276:23667-73.
41. Elrick H, Stimmler L, Hlad Jr CJ, Arai Y. (1964). Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 24:1076-82.
42. Fehmann HC, Goke B. (1995). Characterization of GIP(1-30) and GIP(1-42) as stimulators of proinsulin gene transcription. Peptides 16:1149-52.
43. Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Dore J, Henegar C et al. (2010). Diferential adaptation of human gut microbiota to bariatric surgery-induced weight loss:links with metabolic and low-grade infammation markers. Diabetes 59:3049-57.
44. Gentilella R, Bianchi C, Rossi A, Rotella CM. (2009). Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab 11:544-56.
45. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C. (1999). Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276:R1541-4 (Pubitemid 29249681)
46. Hildebrandt MA, Hofmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, Knight R, Ahima, RS, Bushman F, Wu GD. (2009). High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 137:1716-24 e1-2.
47. Hinke SA, Gelling RW, Pederson RA, Manhart S, Nian C, Demuth HU, McIntosh CH. (2002). Dipeptidyl peptidase IV-resistant [D-Ala(2)] glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 51:652-61. (Pubitemid 34760172)
48. Hojberg PV, Vilsboll T, Rabol R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S. (2009). Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52:199-207.
49. Holdstock C, Engstrom BE, Ohrvall M, Lind L, Sundbom M, Karlsson FA. (2003). Ghrelin and adipose tissue regulatory peptides:efect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 88:3177-83. (Pubitemid 36877491)
50. Holst J J. (2002). Terapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18:430-41. (Pubitemid 36041598)
51. Holz GG, Chepurny OG. (2003). Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 10:2471-83. (Pubitemid 37236400)
52. Hotamisligil GS, Erbay E. (2008). Nutrient sensing and infammation in metabolic diseases. Nat Rev Immunol 8:923-34.
53. Hui H, Tang YG, Zhu L, Khoury N, Hui Z, Wang KY, Perfetti R, Go VL. (2010). Glucagon like peptide-1-directed human embryonic stem cells diferentiation into insulin-producing cells via hedgehog, cAMP, and PI3K pathways. Pancreas 39:315-22.
54. Irwin N, Flatt PR. (2009). Terapeutic potential for GIP receptor agonists and antagonists. Best Pract Res Clin Endocrinol Metab 23:499-512.
55. Irwin N, Gault VA, Green BD, Greer B, Harriott P, Bailey CJ, Flatt PR, O'Harte FP. (2005). Antidiabetic potential of two novel fatty acid derivatised, N-terminally modifed analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). Biol Chem 386: 679-87. (Pubitemid 41448170)
56. Kiefer TJ, Habener JF. (1999). Te glucagon-like peptides. Endocr Rev 20:876-913.
57. Kiefer TJ, McIntosh CH, Pederson RA. (1995). Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-96.
58. Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y, McIntosh CH. (2005). Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 280:22297-307. (Pubitemid 40827886)
59. Kindel TL, Martins PJ, Yoder SM, Jandacek RJ, Seeley RJ, D'Alessio DA, Obici S, Tso P. (2011). Bypassing the duodenum does not improve insulin resistance associated with diet-induced obesity in rodents. Obesity (Silver Spring) 19:380-87.
60. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hofman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. (2009). 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374:1677-86.
61. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. (2007). Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 3:597-601. (Pubitemid 350091417)
62. Laferrere B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Hart AB, Olivan B. (2007). Incretin levels and efect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30:1709-16. (Pubitemid 47036341)
63. Laferrere B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, Kovack B, Bawa B, Koshy N, Lee H, Yapp K, Olivan B. (2008). Efect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 93:2479-85. (Pubitemid 352008510)
64. le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA Patel AG, Bloom SR. (2006). Gut hormone profles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243:108-14. (Pubitemid 43054062)
65. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, Lonroth H, Fandriks L, Ghatei MA, Bloom SR, Olbers T. (2007). Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246:780-85. (Pubitemid 350035654)
66. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. (2005). Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 102:11070-75. (Pubitemid 41105994)
67. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. (2006). Microbial ecology: human gut microbes associated with obesity. Nature 444:1022-3. (Pubitemid 46018512)
68. Li Z, Zhang HY, Lv LX, Li DF, Dai JX, Sha O, Li WQ, Bai Y, Yuan L. (2010). Roux-en-Y gastric bypass promotes expression of PDX-1 and regeneration of beta-cells in Goto-Kakizaki rats. World J Gastroenterol 16:2244-51.
69. Lu M, Wheeler MB, Leng XH, Boyd 3rd AE. (1993). Te role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37). Endocrinology 132:94-100. (Pubitemid 23019487)
70. Madsbad S. (2009). Exenatide and liraglutide:diferent approaches to develop GLP-1 receptor agonists (incretin mimetics)\preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 23:463-77.
71. Malo, MS, Alam, SN, Mostafa, G, Zeller, SJ, Johnson, PV, Mohammad, N, Chen, KT, Moss, AK, Ramasamy, S, Faruqui, A et al. (2010). Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. Gut 59:1476-84.
72. Mason EE, Ito C. (1967). Gastric bypass in obesity. Surg Clin North Am 47:1345-51.
73. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. (2005). An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122:107-18. (Pubitemid 40977944)
74. McIntosh CH, Wheeler MB, Gelling RW, Brown JC, Pederson RA. (1996). GIP receptors and signal-transduction mechanisms. Acta Physiol Scand 157:361-5. (Pubitemid 26226090)
75. McIntosh CH, Widenmaier S, Kim SJ. (2009). Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam Horm 80:409-71.
76. Medzhitov R. (2001). Toll-like receptors and innate immunity. Nat Rev Immunol 1:135-45. (Pubitemid 33741967)
77. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. (2002). Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept 107:1-13. (Pubitemid 34876440)
78. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, Corthesy I, Mace K, Chou CJ. (2008). Gut microbiota modulation with norfoxacin and ampicillin enhances glucose tolerance in mice. FASEB J 22:2416-26. (Pubitemid 351948659)
79. Meneilly GS, Bryer-Ash M, Elahi D. (1993). Te efect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide. Diabetes Care 16:110-14. (Pubitemid 23013833)
80. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S et al. (2002). Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8:738-42. (Pubitemid 34778728)
81. Mojsov S, Weir GC, Habener JF. (1987). Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79:616-9. (Pubitemid 17009701)
82. Montrose-Rafzadeh C, Avdonin P, Garant MJ, Rodgers BD, Kole S, Yang H, Levine MA, Schwindinger W, Bernier M. (1999). Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 140:1132-40. (Pubitemid 29104213)
83. Moore B. (1906). On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane. Biochem J 1:28-38.
84. Moran TH, Smedh U, Kinzig KP, Scott KA, Knipp S, Ladenheim EE. (2005). Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 288:R384-8 (Pubitemid 40129602)
85. Muccioli GG, Naslain D, Backhed F, Reigstad CS, Lambert DM, Delzenne NM, Cani PD. (2010). Te endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 6:392.
86. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. (1992). Lack of efect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects. Digestion 52:214-21.
87. Nauck MA, Heimesaat MM, Orskov C, Holst J J, Ebert R, Creutzfeldt W. (1993a). Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-7. (Pubitemid 23037285)
88. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. (1993b). Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-4. (Pubitemid 23218642)
89. Neish AS. (2009). Microbes in gastrointestinal health and disease. Gastroenterology 136:65-80.
90. Patriti A, Facchiano E, Annetti C, Aisa MC, Galli F, Fanelli C, Donini A. (2005). Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes Surg 15:1258-64. (Pubitemid 41565122)
91. Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK, Maratos-Flier E, Mun EC, Pihlajamaki J et al. (2009). Serum bile acids are higher in humans with prior gastric bypass:potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 17:1671-7.
92. Pederson RA, Schubert HE, Brown JC. (1975). Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog. Diabetes 24:1050-56. (Pubitemid 8016282)
93. Piteau S, Olver A, Kim SJ, Winter K, Pospisilik JA, Lynn F, Manhart S, Demuth HU, Speck M, Pederson RA, McIntosh CH. (2007). Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun 362:1007-12. (Pubitemid 47398873)
94. Pittner RA, Moore CX, Bhavsar SP, Gedulin BR, Smith PA, Jodka CM, Parkes DG, Paterniti JR, Srivastava VP, Young AA. (2004). Efects of PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 28:963-71. (Pubitemid 38998700)
95. Polak JM, Bloom SR, Kuzio M, Brown JC, Pearse AG. (1973). Cellular localization of gastric inhibitory polypeptide in the duodenum and jejunum. Gut 14:284-8.
96. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM, et al. (1995). Who would have thought it? An operation proves to be the most efective therapy for adult-onset diabetes mellitus. Ann Surg 222:339-50; discussion 350-2.
97. Porter DW, Irwin N, Flatt PR, Holscher C, Gault VA. (2011). Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. Eur J Pharmacol 650:688-93.
98. Pradhan A. (2007). Obesity, metabolic syndrome, and type 2 diabetes: infammatory basis of glucose metabolic disorders. Nutr Rev 65:S152-6
99. Rakof-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. (2004). Recognition of commensal microfora by toll-like receptors is required for intestinal homeostasis. Cell 118:229-41. (Pubitemid 38962578)
100. Rodriguez-Grunert L, Galvao Neto MP, Alamo M, Ramos AC, Baez PB, Tarnof M. (2008). First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis 4:55-9.
101. Round JL, Mazmanian SK. (2010). Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA 107:12204-9.
102. Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M, Marescaux J. (2006). Te mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 244:741-9. (Pubitemid 44629948)
103. Rubino F, Marescaux J. (2004). Efect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 239:1-11. (Pubitemid 38176365)
104. Rubino F, Schauer PR, Kaplan LM, Cummings DE. (2010). Metabolic surgery to treat type 2 diabetes:clinical outcomes and mechanisms of action. Annu Rev Med 61:393-411.
105. Rubino F, Zizzari P, Tomasetto C, Bluet-Pajot MT, Forgione A, Vix M, Grouselle D, Marescaux J. (2005). Te role of the small bowel in the regulation of circulating ghrelin levels and food intake in the obese Zucker rat. Endocrinology 146:1745-51. (Pubitemid 40396883)
106. Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E et al. (2003). Efect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 238:467-84; discussion 84-5.
107. Scopinaro N Papadia F, Marinari G, Camerini G, Adami, G. (2007). Long-term control of type 2 diabetes mellitus and the other major components of the metabolic syndrome after biliopancreatic diversion in patients with BMI < 35 kg/m2. Obes Surg 17:185-92 (Pubitemid 47091579)
108. Sekirov I, Russell SL, Antunes LC, Finlay BB. (2010). Gut microbiota in health and disease. Physiol Rev 90:859-904.
109. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. (2006). TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116:3015-25. (Pubitemid 44684486)
110. Sileno AP, Brandt GC, Spann BM, Quay SC. (2006). Lower mean weight after 14 days intravenous administration peptide YY3-36 (PYY3-36) in rabbits. Int J Obes (Lond) 30:68-72. (Pubitemid 41790779)
111. Strader AD, Vahl TP, Jandacek RJ, Woods SC, D'Alessio DA, Seeley RJ. (2005). Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 288:E447-53 (Pubitemid 40110655)
112. Sundbom M, Holdstock C, Engstrom BE, Karlsson FA. (2007). Early changes in ghrelin following Roux-en-Y gastric bypass:infuence of vagal nerve functionality? Obes Surg 17:304-10. (Pubitemid 46659288)
113. Taler JP, Cummings DE. (2009). Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 150:2518-25.
114. Tomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M et al. (2009). TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10:167-77.
115. Torens B. (1992). Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA. 89:8641-5.
116. Torkildsen C, Neve S, Larsen BD, Meier E, Petersen JS. (2003). Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ter 307:490-96. (Pubitemid 37310661)
117. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. (2002). Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51:1443-52. (Pubitemid 34826610)
118. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B. (2001). Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin- treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50:1562-70. (Pubitemid 33639596)
119. Trumper A, Trumper K, Horsch D. (2002). Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 174:233-46. (Pubitemid 34965762)
120. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. (2008). Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3:213-23. (Pubitemid 351494716)
121. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027-31. (Pubitemid 46018515)
122. Unger RH, Eisentraut AM. (1969). Entero-insular axis. Arch Intern Med 123:261-6.
123. van den Hoek AM, Heijboer AC, Corssmit EP, Voshol PJ, Romijn JA, Havekes LM, Pijl H. (2004). PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes 53:1949-52. (Pubitemid 38970740)
124. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight, R, Ley RE, Gewirtz AT. (2010). Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328:228-31.
125. Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ. (2006). PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 291:R367-75 (Pubitemid 44035643)
126. Wang PY, Caspi L, Lam CK, Chari M, Li X, Light PE, Gutierrez-Juarez R, Ang M, Schwartz GJ, Lam TK. (2008). Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature 452:1012-16. (Pubitemid 351589616)
127. Wang Y Montrose-Rafzadeh C, Adams L, Raygada M, Nadiv O, Egan JM. (1996). GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells. Mol Cell Endocrinol 116:81-7. (Pubitemid 26033020)
128. Widenmaier SB, Ao Z, Kim SJ, Warnock G, McIntosh CH. (2009). Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival efects of glucose-dependent insulinotropic polypeptide. J Biol Chem 284:30372-82.
129. Widenmaier SB, Kim SJ, Yang GK, De Los Reyes T, Nian C, Asadi A, Seino Y Kiefer TJ, Kwok YN, McIntosh CH. (2010). A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control. PLoS One 5:e9590.
130. Woodard GA, Encarnacion B, Downey JR, Peraza J, Chong K, Hernandez-Boussard T, Morton JM. (2009). Probiotics improve outcomes after Roux-en-Y gastric bypass surgery:a prospective randomized trial. J Gastrointest Surg 13:1198-204.
131. Wren AM, Bloom SR. (2007). Gut hormones and appetite control. Gastroenterology 132:2116-30. (Pubitemid 46693747)
132. Xu G, Stofers DA, Habener J F, Bonner-Weir S. (1999). Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-76. (Pubitemid 30395416)
133. Xu J, Gordon JI. (2003). Honor thy symbionts. Proc Natl Acad Sci USA 100:10452-9. (Pubitemid 37071899)
134. Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y Parameswaran P, Crowell MD, Wing R, Rittmann BE, Krajmalnik-Brown R. (2009). Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 106:2365-70.